Does smoking influence survival in cancer patients through effects on respiratory and vascular disease?

Patients with cancers caused by smoking may die because they continue to smoke even after diagnosis of a cancer caused by smoking. We investigated differences in cause-specific mortality between patients diagnosed with smoking-related and non-smoking-related cancers. The causes of death were classified as smoking-related cancer, non-smoking-related cancer, respiratory or vascular disease, and all other causes. We studied all 220 089 people diagnosed with cancer in Scotland between 1986 and 1996, aged between 20 and 85 years, with last follow-up on 31 December 1999. There was a moderate excess risk of dying from respiratory and vascular causes in those with smoking-related cancers, which did not fall with time since diagnosis, consistent with continued smoking by these patients. Mortality among cancer patients might fall if more assistance in stopping smoking was provided for patients who have smoking-related cancers.

Longitudinal analysis of the effect of prenatal nicotine exposure on subsequent smoking behavior of offspring.

We explored the influence of maternal smoking during pregnancy on the likelihood of smoking among offspring in adolescence and adulthood using data from two similar British birth cohort surveys, the 1958 National Child Development Study and the 1970 British Birth Survey. Similar information was available in each cohort on maternal age at delivery, offspring sex, maternal smoking during pregnancy, parental and offspring socioeconomic status, and parental smoking at the time offspring smoking was assessed at age 16 years. Offspring smoking at 16 years and at 30/33 years were the primary outcomes of interest. Our data support an association between maternal smoking during pregnancy and an increased risk of offspring smoking later in life among female offspring but not among male offspring. Female offspring of mothers who smoked during pregnancy were more likely to smoke at 16 years than were their male counterparts. Moreover, in this same subgroup, female offspring smoking at 16 years was associated with an increased likelihood of smoking at 30/33 years. Further investigation in larger studies with greater detail of factors shaping smoking in childhood and adulthood and biochemically verified outcome measures would be desirable to clarify the relationship.

Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt.

The objective of this study was to assess the feasibility and success of Zyban as part of a moderately supported smoking cessation programme within UK general practice. Treatment was offered to 479 moderately dependent smokers (smoking 15 or more cigarettes per day) who had never used Zyban, and who had taken part in a previous NRT trial (the PATCH study). Main outcome measures were point prevalence and continuous abstinence from smoking at 6 and at 12 months. Two hundred and forty were excluded because of medical reasons or prescribing contraindication. Of the remainder (n=239) only 54 (23%) made an active quit attempt. Thirty percent (16/54) were abstinent at six months, and 22% (12/54) at 12 months (biochemically validated point prevalence rates). Age, socio-economic status, nicotine dependence, and genetic profile appeared to have little impact on success rates, but male quit-attempters were significantly more successful than female (40% vs. 10% at 12 months, p<0.05). In conclusion, a real-world smoking cessation programme using Zyban with moderate support within a general practice setting may achieve satisfactory quit rates without widening existing disparities in cessation.